+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis



Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis



Biomed Research International 2018: 1969474



To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.3 software and Stata version 12.0. And relative risks (RRs) for survival rate were calculated. A fixed-effect model was selected to pool and a forest plot was used to display RRs. Four studies involving 394 animals were finally included. Nine control groups are used to pool. A fixed-effect model was applied to estimate a pooled RR of 2.19 (95% CI: 1.74-2.76), indicating that PD-1 related blockade increased survival rate in sepsis animals. We concluded that PD-1 related blockade can improve survival of animals with sepsis. But robust standardized clinical experiments for sepsis patients are highly desirable.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065890773

Download citation: RISBibTeXText

PMID: 30159323

DOI: 10.1155/2018/1969474


Related references

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest 152(2): 271-281, 2017

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis. Indian Journal of Urology 35(2): 101-115, 2019

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. ImmunoTherapy 10(15): 1303-1313, 2018

Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Medicine 98(16): E15201, 2019

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer 36(1): 61, 2018

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. Medicine 95(11): E3134, 2016

Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. Journal of Clinical Oncology 35(24): 2735-2736, 2017

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 36(28): 2872-2878, 2018

Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer. Journal of Thoracic Disease 10(12): 6711-6721, 2019

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis. Chinese Medical Journal 130(8): 986-992, 2017

Programmed death-1/programmed death-ligand 1 pathway and T cell exhaustion in sepsis. Zhonghua Nei Ke Za Zhi 58(2): 158-160, 2019

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Medicine 97(43): E12858, 2018

Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. Plos One 12(6): E0179536, 2017

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy. Recent Patents on Anti-Cancer Drug Discovery 11(2): 141-151, 2017

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 9: 1494, 2019